Can cutting out the main tumor boost survival for advanced lung cancer patients?
NCT ID NCT07177092
Summary
This study is testing if surgically removing the main lung tumor before starting the targeted drug osimertinib works better than just taking the drug alone for patients with advanced EGFR-mutant lung cancer. About 118 patients will be randomly assigned to get either the surgery-drug combination or just the drug. The main goal is to see if the combination helps patients live longer without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.